Literature DB >> 25982245

Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.

Ainhoa Oguiza1, Carlota Recio, Iolanda Lazaro, Beñat Mallavia, Julia Blanco, Jesus Egido, Carmen Gomez-Guerrero.   

Abstract

AIMS/HYPOTHESIS: The canonical nuclear factor-κB (NF-κB) pathway mediated by the inhibitor of NF-κB kinase (IKK) regulates the transcription of inflammatory genes involved in the pathogenesis of diabetes, from the early phase to progression and final complications. The NF-κB essential modulator binding domain (NBD) contained in IKKα/β is essential for IKK complex assembly. We therefore investigated the functional consequences of targeting the IKK-dependent NF-κB pathway in the progression of diabetes-associated nephropathy and atherosclerosis.
METHODS: Apolipoprotein E-deficient mice with diabetes induced by streptozotocin were treated with a cell-permeable peptide derived from the IKKα/β NBD region. Kidneys and aorta were analysed for morphology, leucocyte infiltrate, collagen, NF-κB activity and gene expression. In vitro studies were performed in renal and vascular cells.
RESULTS: NBD peptide administration did not affect the metabolic severity of diabetes but resulted in renal protection, as evidenced by dose-dependent decreases in albuminuria, renal lesions (mesangial expansion, leucocyte infiltration and fibrosis), intranuclear NF-κB activity and proinflammatory and pro-fibrotic gene expression. Furthermore, peptide treatment limited atheroma plaque formation in diabetic mice by decreasing the content of lipids, leucocytes and cytokines and increasing plaque stability markers. This nephroprotective and anti-atherosclerotic effect was accompanied by a decline in systemic T helper 1 cytokines. In vitro, NBD peptide prevented IKK assembly/activation, p65 nuclear translocation, NF-κB-regulated gene expression and cell proliferation induced by either high glucose or inflammatory stimulation. CONCLUSIONS/
INTERPRETATION: Peptide-based inhibition of IKK complex formation attenuates NF-κB activation, suppresses inflammation and retards the progression of renal and vascular injury in diabetic mice, thus providing a feasible approach against diabetes inflammatory complications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25982245     DOI: 10.1007/s00125-015-3596-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

Review 1.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

2.  Fluvastatin inhibits high glucose-induced nuclear factor kappa B activation in renal tubular epithelial cells.

Authors:  Ping Gao; Xiaoyan Wu; Hua Shui; Ruhan Jia
Journal:  J Nephrol       Date:  2012-05-18       Impact factor: 3.902

Review 3.  NF-κB in immunobiology.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

Review 4.  NF-κB, inflammation, and metabolic disease.

Authors:  Rebecca G Baker; Matthew S Hayden; Sankar Ghosh
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

5.  Novel anti-diabetic effect of SCM-198 via inhibiting the hepatic NF-κB pathway in db/db mice.

Authors:  Hui Huang; Hong Xin; Xinhua Liu; Yajun Xu; Danyi Wen; Yahua Zhang; Yi Zhun Zhu
Journal:  Biosci Rep       Date:  2012-04-01       Impact factor: 3.840

6.  Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells.

Authors:  Purificación Hernández-Vargas; Oscar López-Franco; Guillermo Sanjuán; Mónica Rupérez; Guadalupe Ortiz-Muñoz; Yusuke Suzuki; Pablo Aguado-Roncero; Gloria Pérez-Tejerizo; Julia Blanco; Jesús Egido; Marta Ruiz-Ortega; Carmen Gómez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2005-04-13       Impact factor: 10.121

Review 7.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

Review 8.  Inflammation and immunity in diabetic vascular complications.

Authors:  Jan Nilsson; Eva Bengtsson; Gunilla Nordin Fredrikson; Harry Björkbacka
Journal:  Curr Opin Lipidol       Date:  2008-10       Impact factor: 4.776

Review 9.  Atherosclerotic plaque stability--what determines the fate of a plaque?

Authors:  Bente Halvorsen; Kari Otterdal; Tuva B Dahl; Mona Skjelland; Lars Gullestad; Erik Øie; Pål Aukrust
Journal:  Prog Cardiovasc Dis       Date:  2008 Nov-Dec       Impact factor: 8.194

10.  Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes.

Authors:  Fadia Mahmoud; Ebaa Al-Ozairi
Journal:  Dis Markers       Date:  2013-09-09       Impact factor: 3.434

View more
  14 in total

Review 1.  Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance.

Authors:  Kalyana C Nandipati; Saravanan Subramanian; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2016-11-21       Impact factor: 3.396

2.  Hyoscyamus albus nortropane alkaloids reduce hyperglycemia and hyperinsulinemia induced in HepG2 cells through the regulation of SIRT1/NF-kB/JNK pathway.

Authors:  Anna Kowalczuk; Nabila Bourebaba; Katarzyna Kornicka-Garbowska; Eliza Turlej; Krzysztof Marycz; Lynda Bourebaba
Journal:  Cell Commun Signal       Date:  2021-05-25       Impact factor: 5.712

3.  LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy.

Authors:  Hong Yi; Rui Peng; Lu-Yu Zhang; Yan Sun; Hui-Min Peng; Han-Deng Liu; Li-Juan Yu; Ai-Ling Li; Ya-Juan Zhang; Wen-Hao Jiang; Zheng Zhang
Journal:  Cell Death Dis       Date:  2017-02-02       Impact factor: 8.469

Review 4.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

5.  Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation.

Authors:  Jing Zhao; Lei Zhang; Xiaodong Mu; Christelle Doebelin; William Nguyen; Callen Wallace; Daniel P Reay; Sara J McGowan; Lana Corbo; Paula R Clemens; Gabriela Mustata Wilson; Simon C Watkins; Laura A Solt; Michael D Cameron; Johnny Huard; Laura J Niedernhofer; Theodore M Kamenecka; Paul D Robbins
Journal:  PLoS Biol       Date:  2018-06-11       Impact factor: 8.029

6.  Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept.

Authors:  Zhengtao Qin; Carl K Hoh; Emilia S Olson; Amin Haghighat Jahromi; David J Hall; Christopher V Barback; Young-Hyun You; Motoko Yanagita; Kumar Sharma; David R Vera
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

7.  Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling.

Authors:  Raquel Rodrigues-Diez; Cristian González-Guerrero; Carlos Ocaña-Salceda; Raúl R Rodrigues-Diez; Jesús Egido; Alberto Ortiz; Marta Ruiz-Ortega; Adrián M Ramos
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

Review 8.  The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy.

Authors:  Shudong Wang; Lijuan Ding; Honglei Ji; Zheng Xu; Quan Liu; Yang Zheng
Journal:  Int J Mol Sci       Date:  2016-06-30       Impact factor: 5.923

9.  Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy.

Authors:  Lucas Opazo-Ríos; Anita Plaza; Yenniffer Sánchez Matus; Susana Bernal; Laura Lopez-Sanz; Luna Jimenez-Castilla; Daniel Carpio; Alejandra Droguett; Sergio Mezzano; Jesús Egido; Carmen Gomez-Guerrero
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

10.  Trichosanthes kirilowii lectin alleviates diabetic nephropathy by inhibiting the LOX1/NF-κB/caspase-9 signaling pathway.

Authors:  Jiandong Lu; Jinting Peng; Min Xiang; Liangping He; Dongcai Wang; Guoliang Xiong; Shunmin Li
Journal:  Biosci Rep       Date:  2018-09-07       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.